Testimony Before the FDA’s Drug Safety and Risk Management Advisory Committee and Anesthetic and Analgesic Drug Products Advisory Committee Regarding Intravenous Tramadol
In testimony before a joint meeting of the Food and Drug Administration’s (FDA’s) Drug Safety and Risk Management Advisory Committee and Anesthetic and Analgesic Drug Products Advisory Committee, Public Citizen urged the committees to recommend that the FDA not approve an intravenous form of tramadol, a widely used but inadequately regulated opioid, for treatment of acute pain in a medically supervised health care setting.
See Public Citizen’s other work on tramadol.
See Public Citizen’s other work on opioid drug issues.